Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 7/20 | 0.33 |
| ▸ | CKS1B | P61024 | 3/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 3/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LIPC | P11150 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4125903 | 0.83 | NAMPT (0.38) | SLC40A1NAMPTLIPGTDP1LIPC | |
| SCHEMBL4126978 | 0.83 | NAMPT (0.34) | SLC40A1NAMPTCKS1BSKP2FEN1 | |
| Fumaric Acid SCHEMBL3652346 | 0.82 | TBXAS1 (0.34) | SLC40A1NAMPTCKS1BSKP2FEN1 | |
| Fumaric Acid SCHEMBL4120381 | 0.82 | TBXAS1 (0.34) | SLC40A1NAMPTCKS1BSKP2FEN1 | |
| SCHEMBL4117665 | 0.81 | LIPG (0.34) | NAMPTLIPGLIPC | |
| SCHEMBL3782033 | 0.80 | NAMPT (0.37) | SLC40A1NAMPTCKS1BSKP2FEN1 | |
| SCHEMBL3650985 | 0.80 | CYP2A6 (0.39) | SLC40A1CKS1BSKP2FEN1CYP17A1 | |
| SCHEMBL4125700 | 0.80 | ALDH1A1 (0.38) | NAMPT | |
| SCHEMBL4130748 | 0.80 | POLB (0.36) | SLC40A1NAMPTCKS1BSKP2TDP1 | |
| SCHEMBL4126636 | 0.79 | GAA (0.39) | NAMPTHSD17B1HSD17B2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC40A1 2890/4885NAMPT 2129/4885CKS1B 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.